Regeneron
Last updated Jun 16, 2026
Evidence Sources
2
Competitive Findings
0
Portfolio Developments
0
Regulatory Precedents
8
Clinical Programs
0
Confidence Coverage
69%
Audit
- Competitor findings: 0
- Portfolio developments: 0
- Self-competition findings removed: 0
- Unknown ownership findings removed: 0
Executive Summary
Material intelligence activity detected across:
- Oncology
- Skin Cancer
- Melanoma
Highest priority development: Janus Kinase (JAK) inhibitors: Drug Safety Communication - FDA Requires Warnings about Increased Risk of Serious Heart-related Events, Cancer, Blood Clots, and Death
Regulatory precedent
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Regeneron.
Competitive pressure: Low
Portfolio impact: High
Evidence coverage: 69%
Active Signals
2
Investigate Priority
0
Opportunity Score
53
Buyer Quality
10 · Enterprise
Recent Signals
Latest intelligence events linked to this organization.
- MonitorJun 16, 2026Score 30CMP-001 and Nivolumab Show Promise in Advanced Melanoma Phase 2/3 Trial
Oncology · Melanoma
- MonitorJun 17, 2026Score 23Phase III Trial Evaluates Cemiplimab with Surgery for Advanced Skin Cancer
Oncology · Skin Cancer
Related Assets
Portfolio asset pages with evidence-based assessments.
No linked asset pages are available yet.
Portfolio Development
Owned-asset pipeline events — Phase III readouts, approvals, label expansions, and deals. Not classified as competitive threats.
No portfolio development items are linked to this company yet.
Competitive Intelligence Findings
Competitiva findings with evidence, reasoning, and confidence calibration.
No Competitiva findings are linked to this company yet.
Regulatory Developments
Regunera precedents with source attribution and confidence disclosure.
- Janus Kinase (JAK) inhibitors: Drug Safety Communication - FDA Requires Warnings about Increased Risk of Serious Heart-related Events, Cancer, Blood Clots, and DeathModerate Confidence · 65%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - Sunscreen: How to Help Protect Your Skin from the SunModerate Confidence · 65%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - S9 Nonclinical Evaluation for Anticancer Pharmaceuticals--Questions and AnswersModerate Confidence · 65%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA approves capivasertib with abiraterone and prednisone for PTEN-deficient androgen pathway modulation-naïve or -sensitive prostate cancerModerate Confidence · 83%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera
Clinical Developments
Pipeline activity with auditable evidence and uncertainty disclosure.
No clinical developments are linked yet.
Investigate-Priority Items
Signals flagged for investigation or escalation — highest urgency for portfolio review.
No investigate-priority signals are active for this company.
Humanexa Agent Questions
Suggested prompts to explore this organization's intelligence profile. Open a linked signal to ask the agent.
- What are the most material competitive threats to Regeneron right now?
- Which regulatory precedents should Regeneron monitor in Oncology and Skin Cancer?
- Which pipeline programs should Regeneron prioritize for competitive review?
- What signals require immediate investigation for Regeneron?
- Summarize the strategic implications of recent developments for Regeneron.
- Where is the greatest uncertainty in Regeneron's competitive positioning?